Abivax S.A. (ABVX) Key Statistics & Financial Ratios

Abivax S.A. (ABVX) — Price $106.37 — Healthcare — Biotechnology — NASDAQ

Latest reported results:

Key statistics dashboard for Abivax S.A. (ABVX). Valuation multiples (P/E, P/B, EV/EBITDA), profitability margins, financial-health ratios, per-share metrics and stock-level data in one consolidated view — the snapshot quantitative analysts and value investors check first.

Abivax S.A., operating as ABIVAX Société Anonyme, is a French pharmaceutical firm focused on the discovery and optimization of therapeutic drugs for inflammatory, infectious, and oncological diseases. A cornerstone of their product pipeline is ABX464, which is currently undergoing Phase IIb clinical trials for ulcerative colitis, Crohn's Disease, and COVID-19.

Stock Data

Price$106.37
Market Cap$7.8B
Enterprise Value$7.70B
Beta-0.10
ExchangeNASDAQ
CountryFR

Valuation Multiples

P/E Ratio-18.73
Price / Book13.82
P/S0.00
EV/EBITDA-30.84
EV/Sales0.00
EV/FCF-47.44
P/FCF-48.60
Earnings Yield-5.16%
FCF Yield-1.99%
Dividend Yield0.00%

Profitability

Gross Margin0.00%
EBIT Margin0.00%
EBITDA Margin0.00%
Operating Margin0.00%
Net Margin0.00%
Return on Equity-165.19%
Return on Assets-57.52%
Return on Invested Capital-45.51%
Return on Capital Employed-48.08%

Financial Health

Current Ratio8.75
Quick Ratio8.75
Cash Ratio8.20
Debt / Equity0.10
Debt / Assets7.85%
Net Debt / EBITDA1.89
Interest Coverage-8.79
Piotroski F-Score4
Altman Z-Score34.93

Per-Share Data

Revenue per share0.00
Book Value per share6.55
Cash per share7.63
FCF per share-2.33
Tangible Book Value per share6.19
Dividend per share0.00

Related companies: AXSM · CORT · CYTK · HALO · JAZZ · MDGL · MRUS

Explore sector: Healthcare · Biotechnology

More sections of ABVX: Overview · Financials · Valuation · Estimates · Technical · Ownership · News · Events

Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks